Hikma Pharmaceuticals Plc (LON:HIK) has been assigned a consensus rating of “Hold” from the seven analysts that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is GBX 1,691.17 ($22.10).
A number of research analysts have recently commented on the company. Peel Hunt raised Hikma Pharmaceuticals to an “add” rating and increased their price objective for the company from GBX 1,160 ($15.16) to GBX 1,950 ($25.48) in a report on Thursday, August 16th. Numis Securities lowered Hikma Pharmaceuticals to a “hold” rating and set a GBX 1,560 ($20.38) price objective on the stock. in a report on Thursday, August 9th. Barclays reissued an “underweight” rating on shares of Hikma Pharmaceuticals in a report on Friday, August 10th. JPMorgan Chase & Co. increased their price objective on Hikma Pharmaceuticals from GBX 1,050 ($13.72) to GBX 1,900 ($24.83) and gave the company a “neutral” rating in a report on Tuesday. Finally, Citigroup increased their price objective on Hikma Pharmaceuticals from GBX 1,675 ($21.89) to GBX 2,100 ($27.44) and gave the company a “buy” rating in a report on Monday, August 20th.
Shares of HIK traded down GBX 23.50 ($0.31) during midday trading on Thursday, reaching GBX 1,661.50 ($21.71). 293,926 shares of the stock were exchanged, compared to its average volume of 822,138. Hikma Pharmaceuticals has a 12-month low of GBX 814.20 ($10.64) and a 12-month high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Featured Article: How to interpret a stock’s beta number
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.